The company highlighted a backlog of approximately $13.8 million as of December 31, 2025, which provides revenue visibility into 2026 and beyond. Odysight.ai ended the year with a cash balance of around $26 million and no debt, positioning itself well for future growth. The increase in operating expenses to $19 million reflects the company's strategic investments in product development and market expansion.
CEO Yehu Ofer stated, "2025 was a transformative year for Odysight.ai. We successfully transitioned from our legacy medical business and are now fully focused on the high-value aerospace, defense, and industrial sectors where our technology delivers the greatest impact." The company has made significant strides in delivering systems for UAVs and has expanded into high-volume industrial markets, receiving its first commercial purchase order for 200 predictive monitoring systems.
Looking ahead, Odysight.ai is exploring a potential dual listing on the Tel Aviv Stock Exchange to enhance access to investors. CFO Einav Brenner emphasized the importance of monetizing the backlog and pursuing additional contracts to expand the order book. The company remains optimistic about its growth trajectory as it continues to innovate and capture market share in its targeted sectors.
